Autopsy report · NCT00754221
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
Cause of deathFunding or business
“This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 1 year before it stopped.
- 390 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Fibromyalgia
- Interventions
- [S,S]-Reboxetine
- Participants
- 390
- Sites
- 109
- Countries
- Canada, United States
Trials that died the same way
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety” - A Study of Tadalafil for Duchenne Muscular Dystrophy
“The study is being terminated for lack of efficacy” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
“The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.